TGTX on XNAS, Health Care, TG Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Shares up 108% in a year as revenue rose 69%, but 12-month profit fell 76%.
BadShort interest is 19% of shares, with 18.9 days to cover
GoodInstitutional holders rose 6.1% to 449 from 423 last quarter
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $259.9M, net income $55.5M.
31 Dec 2021RevenueNet incomeNet losstallest bar $390.9M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$259.9M
$55.5M
30 Jun 2026
$240.3M
$7.8M
31 Mar 2026
$204.9M
$19.8M
31 Dec 2025
$192.6M
$23.0M
30 Sep 2025
$161.7M
$390.9M
30 Jun 2025
$141.1M
$28.2M
31 Mar 2025
$120.9M
$5.1M
31 Dec 2024
$108.2M
–
30 Sep 2024
$83.9M
$3.9M
30 Jun 2024
$73.5M
$6.9M
31 Mar 2024
$63.5M
-$10.7M
31 Dec 2023
$44.0M
-$14.4M
30 Sep 2023
$165.8M
$113.9M
30 Jun 2023
$16.1M
-$47.6M
31 Mar 2023
$7.8M
-$39.2M
31 Dec 2022
$80K
-$53.0M
30 Sep 2022
$94K
-$35.8M
30 Jun 2022
$594K
-$40.5M
31 Mar 2022
$2.0M
-$69.0M
31 Dec 2021
$2.3M
-$93.3M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$897.8M
$531.9M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+69%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$106.1M
$447.5M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$0.67
$2.79
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
82.7%
85.3%
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
21.5%
19.3%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
11.8%
84.1%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
18.0%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$85.6M
-$70.2M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$556.7M
$178.3M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$745.6M
$245.3M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$188.9M
$67.0M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
1.3
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$3.79
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
90.3
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
10.7
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
10.9
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
16.7
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$275K
bought $0, sold $275K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+6.1%
449 13F filers vs 423
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
77%
116.4M shares held by 13F filers (30 Sep 2026) of 151.1M outstanding (4 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
19%
28.8M shares sold short (30 Oct 2026) of 151.1M outstanding (4 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
18.9
28.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-2.8%
29.6M shares sold short in the report before, 28.8M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
50%
50% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 49%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+61%
$259.9M vs $161.7M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
22
22 articles in the last 7 days; its usual week has 4 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
5.5×
22 articles in the last 7 days; its usual week has 4.
Price $63.34 on 20 Nov 2026, +108% over 12 months (12-month range $26.94 to $66.12)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $275K in the last 12 months (the 12 months before: -$1.8M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.Revenue per quarter. Revenue $259.9M in the latest quarter, +61% on a year earlier.Capital spending per quarter. Capital spending $282K in the latest quarter, +252% on a year earlier.Institutional holders (13F filers). 449 13F filers reported holding it in the latest 13F quarter, +35% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $2.3M, +6008% on a year earlier; public on 2 Mar 2022
Quarter ended 31 Mar 2022: $2.0M, +154% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $594K, -62% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $94K, -95% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $80K, -97% on a year earlier; public on 2 Mar 2023
Quarter ended 31 Mar 2023: $7.8M, +287% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $16.1M, +2606% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $165.8M, +176299% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $44.0M, +54864% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $63.5M, +713% on a year earlier; public on 7 May 2024
Quarter ended 30 Jun 2024: $73.5M, +357% on a year earlier; public on 10 Aug 2024
Quarter ended 30 Sep 2024: $83.9M, -49% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $108.2M, +146% on a year earlier; public on 4 Mar 2025
Quarter ended 31 Mar 2025: $120.9M, +90% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $141.1M, +92% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $161.7M, +93% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $192.6M, +78% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $204.9M, +70% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $240.3M, +70% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $259.9M, +61% on a year earlier; public on 10 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $80K, -48% on a year earlier; public on 2 Mar 2022
Quarter ended 31 Mar 2022: $7K, -90% on a year earlier; public on 11 May 2022
Quarter ended 30 Sep 2022: $4K, -95% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $3K, -96% on a year earlier; public on 2 Mar 2023
Quarter ended 31 Dec 2023: $0, -100% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $0; public on 10 May 2025
Quarter ended 30 Sep 2024: $24K; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $21K; public on 4 Mar 2025
Quarter ended 31 Mar 2025: $25K; public on 10 May 2025
Quarter ended 30 Jun 2025: $42K; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $80K, +233% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $67K, +219% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $51K, +104% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $293K, +598% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $282K, +252% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 179; public on 14 Feb 2022
31 Mar 2022 report: 167; public on 16 May 2022
30 Jun 2022 report: 161; public on 15 Aug 2022
30 Sep 2022 report: 162; public on 14 Nov 2022
31 Dec 2022 report: 181; public on 14 Feb 2023
31 Mar 2023 report: 198; public on 15 May 2023
30 Jun 2023 report: 226; public on 14 Aug 2023
30 Sep 2023 report: 210; public on 14 Nov 2023
31 Dec 2023 report: 221; public on 14 Feb 2024
31 Mar 2024 report: 229; public on 15 May 2024
30 Jun 2024 report: 241; public on 14 Aug 2024
30 Sep 2024 report: 293; public on 14 Nov 2024
31 Dec 2024 report: 319; public on 14 Feb 2025
31 Mar 2025 report: 357; public on 15 May 2025
30 Jun 2025 report: 334; public on 14 Aug 2025
30 Sep 2025 report: 332; public on 14 Nov 2025
31 Dec 2025 report: 330; public on 17 Feb 2026
31 Mar 2026 report: 353; public on 15 May 2026
30 Jun 2026 report: 423; public on 14 Aug 2026
30 Sep 2026 report: 449; public on 16 Nov 2026
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F holders (funds reporting the stock) at 449 (30 Sep 2026), 1.4× its normal reading; higher than 100% of its own history.
Two or more unrelated kinds of records unusual within 30 days
7 Nov 2023confirmed
Confirmed across sources Filings + Financials and Short interest and volume
TG Therapeutics(TGTX): had 37.2M shares sold short in the 13 Oct 2023 report, 1.9× the same report last year, while it reported revenue of $165.8M for the quarter ended 30 Sep 2023, 1,764× the same quarter last year. Two unrelated kinds of activity within 7 days.
Short interest and volume: Short interest spike, became public on 25 Oct 2023
Financials: Quarterly revenue change, became public on 7 Nov 2023
The 13 Oct 2023 report against the 24 reports before it.
this reportearliernormal: 23.2MSee the evidence (2 changes)
Short interest and volume: Short interest spike became public on 25 Oct 2023
TG Therapeutics had 37.2M shares sold short in the 13 Oct 2023 report, 1.9× the same report last year.
This period
37.2M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
23.2M
Typical spread (median absolute deviation)
2.6M
How far from its usual level
+3.6
Same report last year
19.4M
History used
2,114 days
the 13 Oct 2023 report24 earlier reportsnormal: 23.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 7 Nov 2023
TG Therapeutics reported revenue of $165.8M for the quarter ended 30 Sep 2023, 1,764× the same quarter last year.
This period
$165.8M (the quarter ended 30 Sep 2023)
Normal quarter (median of 8 earlier)
$2.0M
Typical spread (median absolute deviation)
$1.7M
How far from its usual level
+65.8
Same quarter last year
$94K
History used
2,283 days
the quarter ended 30 Sep 20238 earlier quartersnormal: $2.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 Aug 2023confirmed
Confirmed across sources Institutional holdings and Filings + Financials
TG Therapeutics(TGTX): reported revenue of $16.1M for the quarter ended 30 Jun 2023, 27× the same quarter last year, while it saw 51 13F filers open a new position in the quarter ended 30 Jun 2023, 1.9× the same quarter last year. Two unrelated kinds of activity within 7 days.
Financials: Quarterly revenue change, became public on 8 Aug 2023
Institutional holdings: Many funds opening a new position, became public on 14 Aug 2023
The quarter ended 30 Jun 2023 against the 8 quarters before it.
this quarterearliernormal: $1.8MSee the evidence (2 changes)
Financials: Quarterly revenue change became public on 8 Aug 2023
TG Therapeutics reported revenue of $16.1M for the quarter ended 30 Jun 2023, 27× the same quarter last year.
This period
$16.1M (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
$1.8M
Typical spread (median absolute deviation)
$864K
How far from its usual level
+11.2
Same quarter last year
$594K
History used
2,191 days
the quarter ended 30 Jun 20238 earlier quartersnormal: $1.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Institutional holdings: Many funds opening a new position became public on 14 Aug 2023
TG Therapeutics saw 51 13F filers open a new position in the quarter ended 30 Jun 2023, 1.9× the same quarter last year.
This period
51 (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
28
Typical spread (median absolute deviation)
4
How far from its usual level
+3.9
Same quarter last year
27
History used
3,560 days
the quarter ended 30 Jun 20238 earlier quartersnormal: 28
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
16 May 2023confirmed
Confirmed across sources Institutional holdings and Short interest and volume
TG Therapeutics(TGTX): had 28.4M shares sold short in the 31 Mar 2023 report, 1.3× the same report last year, while it saw 47 13F filers open a new position in the quarter ended 31 Mar 2023, 1.8× the same quarter last year. Two unrelated kinds of activity within 28 days.
Short interest and volume: Short interest spike, became public on 13 Apr 2023
Short interest and volume: Short interest spike, became public on 26 Apr 2023
Institutional holdings: Many funds opening a new position, became public on 15 May 2023
The 31 Mar 2023 report against the 24 reports before it.
this reportearliernormal: 20.0MSee the evidence (3 changes)
Short interest and volume: Short interest spike became public on 13 Apr 2023
TG Therapeutics had 28.4M shares sold short in the 31 Mar 2023 report, 1.3× the same report last year.
This period
28.4M (the 31 Mar 2023 report)
Normal report (median of 24 earlier)
20.0M
Typical spread (median absolute deviation)
812K
How far from its usual level
+4.2
Same report last year
21.1M
History used
1,918 days
the 31 Mar 2023 report24 earlier reportsnormal: 20.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Apr 2023
TG Therapeutics had 27.5M shares sold short in the 14 Apr 2023 report, 1.4× the same report last year.
This period
27.5M (the 14 Apr 2023 report)
Normal report (median of 24 earlier)
20.0M
Typical spread (median absolute deviation)
812K
How far from its usual level
+3.7
Same report last year
19.4M
History used
1,932 days
the 14 Apr 2023 report24 earlier reportsnormal: 20.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2023
TG Therapeutics saw 47 13F filers open a new position in the quarter ended 31 Mar 2023, 1.8× the same quarter last year.
This period
47 (the quarter ended 31 Mar 2023)
Normal quarter (median of 8 earlier)
28
Typical spread (median absolute deviation)
3
How far from its usual level
+4.3
Same quarter last year
26
History used
3,469 days
the quarter ended 31 Mar 20238 earlier quartersnormal: 28
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
14 Nov 2024Institutional holdings change
saw 82 13F filers open a new position in the quarter ended 30 Sep 2024, 2.3× the same quarter last year.
Same quarter last year: 35; its normal quarter is 35.
See the evidence
This period
82 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
35
Typical spread (median absolute deviation)
6
How far from its usual level
+5.3
Same quarter last year
35
History used
4,018 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 35
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $73.5M for the quarter ended 30 Jun 2024, 4.6× the same quarter last year.
Same quarter last year: $16.1M; its normal quarter is $11.9M.
See the evidence
This period
$73.5M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$11.9M
Typical spread (median absolute deviation)
$11.9M
How far from its usual level
+3.5
Same quarter last year
$16.1M
History used
2,557 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $11.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $63.5M for the quarter ended 31 Mar 2024, 8.1× the same quarter last year.
Same quarter last year: $7.8M; its normal quarter is $4.9M.
See the evidence
This period
$63.5M (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
$4.9M
Typical spread (median absolute deviation)
$4.8M
How far from its usual level
+8.2
Same quarter last year
$7.8M
History used
2,466 days
the quarter ended 31 Mar 20248 earlier quartersnormal: $4.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $44.0M for the quarter ended 31 Dec 2023, 550× the same quarter last year.
Same quarter last year: $80K; its normal quarter is $2.2M.
See the evidence
This period
$44.0M (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
$2.2M
Typical spread (median absolute deviation)
$2.1M
How far from its usual level
+13.5
Same quarter last year
$80K
History used
2,375 days
the quarter ended 31 Dec 20238 earlier quartersnormal: $2.2M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 37.2M shares sold short in the 13 Oct 2023 report, 1.9× the same report last year, while it reported revenue of $165.8M for the quarter ended 30 Sep 2023, 1,764× the same quarter last year. Two unrelated kinds of activity within 7 days.
See the evidence (2 changes)
Short interest and volume: Short interest spike became public on 25 Oct 2023
TG Therapeutics had 37.2M shares sold short in the 13 Oct 2023 report, 1.9× the same report last year.
This period
37.2M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
23.2M
Typical spread (median absolute deviation)
2.6M
How far from its usual level
+3.6
Same report last year
19.4M
History used
2,114 days
the 13 Oct 2023 report24 earlier reportsnormal: 23.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 7 Nov 2023
TG Therapeutics reported revenue of $165.8M for the quarter ended 30 Sep 2023, 1,764× the same quarter last year.
This period
$165.8M (the quarter ended 30 Sep 2023)
Normal quarter (median of 8 earlier)
$2.0M
Typical spread (median absolute deviation)
$1.7M
How far from its usual level
+65.8
Same quarter last year
$94K
History used
2,283 days
the quarter ended 30 Sep 20238 earlier quartersnormal: $2.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
7 Nov 2023Financials change
reported revenue of $165.8M for the quarter ended 30 Sep 2023, 1,764× the same quarter last year.
Same quarter last year: $94K; its normal quarter is $2.0M.
See the evidence
This period
$165.8M (the quarter ended 30 Sep 2023)
Normal quarter (median of 8 earlier)
$2.0M
Typical spread (median absolute deviation)
$1.7M
How far from its usual level
+65.8
Same quarter last year
$94K
History used
2,283 days
the quarter ended 30 Sep 20238 earlier quartersnormal: $2.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 37.2M shares sold short in the 13 Oct 2023 report, 1.9× the same report last year.
Same report last year: 19.4M; its normal report is 23.2M.
See the evidence
This period
37.2M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
23.2M
Typical spread (median absolute deviation)
2.6M
How far from its usual level
+3.6
Same report last year
19.4M
History used
2,114 days
the 13 Oct 2023 report24 earlier reportsnormal: 23.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $16.1M for the quarter ended 30 Jun 2023, 27× the same quarter last year, while it saw 51 13F filers open a new position in the quarter ended 30 Jun 2023, 1.9× the same quarter last year. Two unrelated kinds of activity within 7 days.
See the evidence (2 changes)
Financials: Quarterly revenue change became public on 8 Aug 2023
TG Therapeutics reported revenue of $16.1M for the quarter ended 30 Jun 2023, 27× the same quarter last year.
This period
$16.1M (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
$1.8M
Typical spread (median absolute deviation)
$864K
How far from its usual level
+11.2
Same quarter last year
$594K
History used
2,191 days
the quarter ended 30 Jun 20238 earlier quartersnormal: $1.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Institutional holdings: Many funds opening a new position became public on 14 Aug 2023
TG Therapeutics saw 51 13F filers open a new position in the quarter ended 30 Jun 2023, 1.9× the same quarter last year.
This period
51 (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
28
Typical spread (median absolute deviation)
4
How far from its usual level
+3.9
Same quarter last year
27
History used
3,560 days
the quarter ended 30 Jun 20238 earlier quartersnormal: 28
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
saw 51 13F filers open a new position in the quarter ended 30 Jun 2023, 1.9× the same quarter last year.
Same quarter last year: 27; its normal quarter is 28.
See the evidence
This period
51 (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
28
Typical spread (median absolute deviation)
4
How far from its usual level
+3.9
Same quarter last year
27
History used
3,560 days
the quarter ended 30 Jun 20238 earlier quartersnormal: 28
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $16.1M for the quarter ended 30 Jun 2023, 27× the same quarter last year.
Same quarter last year: $594K; its normal quarter is $1.8M.
See the evidence
This period
$16.1M (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
$1.8M
Typical spread (median absolute deviation)
$864K
How far from its usual level
+11.2
Same quarter last year
$594K
History used
2,191 days
the quarter ended 30 Jun 20238 earlier quartersnormal: $1.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 28.4M shares sold short in the 31 Mar 2023 report, 1.3× the same report last year, while it saw 47 13F filers open a new position in the quarter ended 31 Mar 2023, 1.8× the same quarter last year. Two unrelated kinds of activity within 28 days.
See the evidence (3 changes)
Short interest and volume: Short interest spike became public on 13 Apr 2023
TG Therapeutics had 28.4M shares sold short in the 31 Mar 2023 report, 1.3× the same report last year.
This period
28.4M (the 31 Mar 2023 report)
Normal report (median of 24 earlier)
20.0M
Typical spread (median absolute deviation)
812K
How far from its usual level
+4.2
Same report last year
21.1M
History used
1,918 days
the 31 Mar 2023 report24 earlier reportsnormal: 20.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Apr 2023
TG Therapeutics had 27.5M shares sold short in the 14 Apr 2023 report, 1.4× the same report last year.
This period
27.5M (the 14 Apr 2023 report)
Normal report (median of 24 earlier)
20.0M
Typical spread (median absolute deviation)
812K
How far from its usual level
+3.7
Same report last year
19.4M
History used
1,932 days
the 14 Apr 2023 report24 earlier reportsnormal: 20.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2023
TG Therapeutics saw 47 13F filers open a new position in the quarter ended 31 Mar 2023, 1.8× the same quarter last year.
This period
47 (the quarter ended 31 Mar 2023)
Normal quarter (median of 8 earlier)
28
Typical spread (median absolute deviation)
3
How far from its usual level
+4.3
Same quarter last year
26
History used
3,469 days
the quarter ended 31 Mar 20238 earlier quartersnormal: 28
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 May 2023Institutional holdings change
saw 47 13F filers open a new position in the quarter ended 31 Mar 2023, 1.8× the same quarter last year.
Same quarter last year: 26; its normal quarter is 28.
See the evidence
This period
47 (the quarter ended 31 Mar 2023)
Normal quarter (median of 8 earlier)
28
Typical spread (median absolute deviation)
3
How far from its usual level
+4.3
Same quarter last year
26
History used
3,469 days
the quarter ended 31 Mar 20238 earlier quartersnormal: 28
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 27.5M shares sold short in the 14 Apr 2023 report, 1.4× the same report last year.
Same report last year: 19.4M; its normal report is 20.0M.
See the evidence
This period
27.5M (the 14 Apr 2023 report)
Normal report (median of 24 earlier)
20.0M
Typical spread (median absolute deviation)
812K
How far from its usual level
+3.7
Same report last year
19.4M
History used
1,932 days
the 14 Apr 2023 report24 earlier reportsnormal: 20.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 28.4M shares sold short in the 31 Mar 2023 report, 1.3× the same report last year.
Same report last year: 21.1M; its normal report is 20.0M.
See the evidence
This period
28.4M (the 31 Mar 2023 report)
Normal report (median of 24 earlier)
20.0M
Typical spread (median absolute deviation)
812K
How far from its usual level
+4.2
Same report last year
21.1M
History used
1,918 days
the 31 Mar 2023 report24 earlier reportsnormal: 20.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 26.6M shares sold short in the 15 Mar 2023 report, 1.4× the same report last year.
Same report last year: 19.0M; its normal report is 19.7M.
See the evidence
This period
26.6M (the 15 Mar 2023 report)
Normal report (median of 24 earlier)
19.7M
Typical spread (median absolute deviation)
870K
How far from its usual level
+3.5
Same report last year
19.0M
History used
1,902 days
the 15 Mar 2023 report24 earlier reportsnormal: 19.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 19.7M shares sold short in the 28 Feb 2022 report, 1.7× the same report last year.
Same report last year: 11.8M; its normal report is 12.4M.
See the evidence
This period
19.7M (the 28 Feb 2022 report)
Normal report (median of 24 earlier)
12.4M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+4.5
Same report last year
11.8M
History used
1,522 days
the 28 Feb 2022 report24 earlier reportsnormal: 12.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 19.0M shares sold short in the 15 Feb 2022 report, 1.6× the same report last year.
Same report last year: 11.8M; its normal report is 12.0M.
See the evidence
This period
19.0M (the 15 Feb 2022 report)
Normal report (median of 24 earlier)
12.0M
Typical spread (median absolute deviation)
888K
How far from its usual level
+5.3
Same report last year
11.8M
History used
1,509 days
the 15 Feb 2022 report24 earlier reportsnormal: 12.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 16.7M shares sold short in the 31 Jan 2022 report, 1.4× the same report last year.
Same report last year: 12.0M; its normal report is 12.0M.
See the evidence
This period
16.7M (the 31 Jan 2022 report)
Normal report (median of 24 earlier)
12.0M
Typical spread (median absolute deviation)
827K
How far from its usual level
+3.8
Same report last year
12.0M
History used
1,494 days
the 31 Jan 2022 report24 earlier reportsnormal: 12.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 16.3M shares sold short in the 14 Jan 2022 report, 1.3× the same report last year.
Same report last year: 12.6M; its normal report is 12.0M.
See the evidence
This period
16.3M (the 14 Jan 2022 report)
Normal report (median of 24 earlier)
12.0M
Typical spread (median absolute deviation)
827K
How far from its usual level
+3.6
Same report last year
12.6M
History used
1,477 days
the 14 Jan 2022 report24 earlier reportsnormal: 12.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 71 13F filers open a new position in the quarter ended 31 Dec 2020, 2.4× the same quarter last year.
Same quarter last year: 30; its normal quarter is 22.
See the evidence
This period
71 (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
22
Typical spread (median absolute deviation)
8
How far from its usual level
+4.1
Same quarter last year
30
History used
2,649 days
the quarter ended 31 Dec 20208 earlier quartersnormal: 22
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 16.9M shares sold short in the 15 Apr 2019 report, 1.6× the same report last year.
Same report last year: 10.5M; its normal report is 10.9M.
See the evidence
This period
16.9M (the 15 Apr 2019 report)
Normal report (median of 24 earlier)
10.9M
Typical spread (median absolute deviation)
943K
How far from its usual level
+4.3
Same report last year
10.5M
History used
472 days
the 15 Apr 2019 report24 earlier reportsnormal: 10.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 17.6M shares sold short in the 29 Mar 2019 report, 1.3× the same report last year.
Same report last year: 14.0M; its normal report is 10.9M.
See the evidence
This period
17.6M (the 29 Mar 2019 report)
Normal report (median of 24 earlier)
10.9M
Typical spread (median absolute deviation)
943K
How far from its usual level
+4.9
Same report last year
14.0M
History used
455 days
the 29 Mar 2019 report24 earlier reportsnormal: 10.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 17.3M shares sold short in the 15 Mar 2019 report, 1.2× the same report last year.
Same report last year: 14.0M; its normal report is 10.9M.
See the evidence
This period
17.3M (the 15 Mar 2019 report)
Normal report (median of 24 earlier)
10.9M
Typical spread (median absolute deviation)
943K
How far from its usual level
+4.6
Same report last year
14.0M
History used
441 days
the 15 Mar 2019 report24 earlier reportsnormal: 10.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Not listed: 180 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001001316
Ticker
TGTX
Domain
tgtherapeutics.com
Employer name
TG Therapeutics, Inc. (1 unverified)
Fein
36-3898269 (1 unverified)
Hq location
NY|NEW YORK|10014 (1 unverified)
Name
Ariston Pharmaceuticals, Inc, ATLANTIC PHARMACEUTICALS INC, ATLANTIC TECHNOLOGY VENTURES INC, MANHATTAN PHARMACEUTICALS INC and 4 more
Uei
JKPZKD19WMD7
Wikidata
Q106301317
DOL H-1B labor condition applications and PERM certifications15 data points13 Nov 2023 to 14 Apr 2025
SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)154 records7 Mar 2016 to 9 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1074 data points31 Dec 2000 to 4 Nov 2026
SEC Form 4 insider transactions36 records, 132 data points7 Jan 2016 to 14 Sep 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026